Last reviewed · How we verify
Hayat Abad Medical Complex, Peshawar — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Topical Clotrimazole cream | Topical Clotrimazole cream | marketed | Imidazole antifungal | Fungal lanosterol 14α-demethylase (CYP51) | Dermatology / Infectious Disease |
Therapeutic area mix
- Dermatology / Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Aesculape CRO Belgium BV · 1 shared drug class
- AmDerma · 1 shared drug class
- Bausch Health Americas, Inc. · 1 shared drug class
- Bayer · 1 shared drug class
- Fakultas Kedokteran Universitas Indonesia · 1 shared drug class
- Galderma R&D · 1 shared drug class
- Jamaica Hospital Medical Center · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Hayat Abad Medical Complex, Peshawar:
- Hayat Abad Medical Complex, Peshawar pipeline updates — RSS
- Hayat Abad Medical Complex, Peshawar pipeline updates — Atom
- Hayat Abad Medical Complex, Peshawar pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Hayat Abad Medical Complex, Peshawar — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hayat-abad-medical-complex-peshawar. Accessed 2026-05-17.